ArticleACS nano2026
Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.
Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer vaccines are designed to activate dendritic cells (DCs), which are potent antigen-presenting cells that initiate antigen-specific adaptive immune responses and inhibit tumor growth. Microneedles (MNs) have emerged as a promising cancer vaccine platform, enabling the noninvasive dermal delivery of cancer antigens and adjuvants to activate dermal DCs. However, conventional solid MNs have a limited surface area, restricting the adsorption of large amounts of bioactive components. Therefore, 3D-printed lattice-structured microarray patches (L-MAPs) with an increased surface area were designed in this study, which permitted the enhanced adsorption of cancer nanovaccines compared to conventional solid microarray patches. L-MAPs were fabricated by using the continuous liquid interface production (CLIP) technology, facilitating the rapid printing of MNs with lattice structures. L-MAPs adsorbed higher amounts of mesoporous-silica-based nanovaccine (MV) on their needle surfaces, exhibiting greater dermal vaccine delivery capacity. Applying MV@MAPs on mouse skin led to efficient DC recruitment, maturation, and subsequent antigen-specific T cell responses in vivo. Consequently, the resulting antitumor immune response considerably suppressed the tumor growth. This approach highlights that using CLIP-printed L-MAPs is a promising strategy for efficient nanovaccine delivery in cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.